RESEARCH MONOGRAPH · KDC-MN-042

CDP-Choline (Citicoline)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

79/100

Solid cholinergic precursor with a side benefit (uridine release) that often gets overlooked

Citicoline is the other serious cholinergic precursor, and honestly the choice between this and alpha-GPC isnt as simple as the marketing makes it sound. The molecule itself doesnt cross the BBB intact. It gets hydrolyzed in the gut and liver to cytidine and choline, and then the cytidine arm becomes uridine via the salvage pathway, which is where things get interesting.

The uridine side of the molecule is the thing thats actually distinctive. Uridine enters CDP-choline biosynthesis in the brain as the rate-limiting step for phosphatidylcholine synthesis, so you're not just supplementing choline, you're driving membrane phospholipid turnover. The Wurtman group at MIT spent decades on this, and the data is actually quite tidy: oral citicoline raises both serum choline and uridine in primates and humans, and brain phosphatidylcholine synthesis goes up downstream.

The clinical evidence is also reasonable. The European stroke work is the strongest piece, with multiple trials showing some functional recovery benefit, although the meta-analyses are mixed. In cognitive aging and vascular cognitive impairment the IDEALE study and a few smaller trials show real effects on attention and memory measures. Not dramatic, but real.

What we like: the dual mechanism (choline plus uridine) is a genuine advantage if membrane synthesis is what you care about. Safety profile is excellent (it's a normal metabolic intermediate). Pharmacokinetics are well-characterized.

What we dont like: the BBB question is real, alpha-GPC delivers choline more directly, and for pure ACh-synthesis-driven work citicoline isnt quite as clean a tool. The uridine angle is interesting but matters more for chronic membrane work than acute cholinergic transmission.

Sourcing is straightforward. It's a commodity molecule with established pharmacopoeia standards, multiple reputable suppliers, and HPLC validation is routine. Stability is good if you keep it dry.

For research where you want to model dietary choline plus uridine support, this is the molecule. For acute cholinergic enhancement, alpha-GPC. They're not interchangeable even though theyre often described that way.

Worth keeping both in the rack honestly. They answer different questions.

Evidence: 75
Mechanism: 80
Reliability: 78
Safety: 85
Sourcing: 85
Value: 78
Signal: 70
Staying power: 80

Plain-language summary Intrigue 66 / 100

CDP-Choline (citicoline) is a nucleotide form of choline used in stroke recovery research and as a cognitive supplement. It supports acetylcholine and phospholipid synthesis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Cholinergic precursor / nucleotide

Cytidine 5'-diphosphocholine, an endogenous nucleotide intermediate in phosphatidylcholine synthesis with neuroprotective and cognitive enhancement applications.

Abstract

Citicoline (cytidine 5'-diphosphocholine, CDP-Choline; CAS 987-78-0; molecular formula C14H26N4O11P2; molecular weight 488.32) is an endogenous nucleotide intermediate in the Kennedy pathway for phosphatidylcholine biosynthesis. Exogenous citicoline is hydrolyzed in the gut to cytidine and choline, which are absorbed independently and reassembled centrally as needed. The bioavailability profile differs from alpha-GPC: citicoline does not cross the blood-brain barrier intact at therapeutic concentrations; the elevation in central choline derives from increased availability of the precursor pools. The compound is approved as a medicine in many countries (Italy, Spain, Japan, Mexico, much of Latin America) for ischemic stroke, traumatic brain injury, and chronic cerebrovascular disease. Large randomized trials (ICTUS, COBRIT) have produced mixed results; meta-analysis suggests modest benefit in acute stroke recovery and chronic cognitive impairment with effect sizes in the 0.2 to 0.4 range. The compound is sold as a dietary supplement in the United States. Pharmacokinetics: plasma half-life of cytidine and choline components is several hours after dissociation; the CDP-Choline structure itself is not detectable in serum after oral administration. Reported research dose ranges in the literature span 500 to 2000 mg. Excellent safety profile with rare serious adverse events.

Mechanism of action

Hydrolyzed in gut to cytidine + choline; both contribute to phosphatidylcholine resynthesis and acetylcholine production. Indirect cholinergic and membrane-stabilizing effects.

Reported research dose ranges

500 to 2000 mg, as reported research dose ranges in the literature.

References

Davalos A, et al. Citicoline in the treatment of acute ischaemic stroke (ICTUS): a multicentre RCT. Lancet 2012.
Zafonte RD, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury (COBRIT). JAMA 2012.
Secades JJ. Citicoline: pharmacological and clinical review. Rev Neurol 2011.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-042

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

CDP-Choline (Citicoline)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs